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Purpose/Objective: This analysis aimed to assess correlations 
between the most relevant acute toxicities (tox) and 
dosimetric risk factors during radiotherapy (RT) for 
nasopharyngeal cancer (NPC) and to identify patients (pts) 
suitable for studies on genetic determinants of radioinduced 
toxicity. 
Materials and Methods: Since 2004, 156 consecutive NPC pts, 
with stages III-IV, received curative Intensity Modulated 
Radiation Therapy (IMRT) with or without chemotherapy 
(CHT) at a median total dose of 70 Gy with standard 
fractionation (2 Gy/fr). Planning data were collected and 
analyzed with a dedicated program (VODCA, www.vodca.ch). 
Acute mucositis, dysphagia and xerostomia were assessed 
according to Common Terminology Criteria for Adverse 
Events (CTCAE v4.0) at baseline and weekly during RT. 
Endpoints of this preliminary analysis were mean grade of 
mucositis ≥ 1.3, grade 3 dysphagia and grade 2 xerostomia 
recorded during RT. The Organs At Risk (OAR) selected as the 
most involved were oral cavity (OC) for mucositis; OC, 
pharyngeal constrictor muscles (PCM) and supraglottic larynx 
(SL) for dysphagia and OC and parotid glands for xerostomia. 
For those OARs, average DVHs of pts with/without each 
toxicity endpoint were compared through two-sided t-tests to 
assess the most discriminative values, according to the 
lowest p-values. Logistic uni- and multi-variate (MVA) analysis 
were performed, including selected dosimetric and clinical 
variables: a backward feature selection method based on 
prediction optimization (minimization of residual) was 
implemented in the KNIME (www.knime.com) environment. 
Residuals were used to identify the subpopulation to be 
selected for future genetic studies (i.e. pts with higher/lower 
toxicity with respect to the MVA prediction). 
Results: Complete dosimetric data were available for 128 
pts. Mean grade mucositis ≥ 1.3 was reported in 43 pts (32%), 
grade ≥ 3 dysphagia in 49 pts (37%) and grade ≥ 2 xerostomia 
in 89 pts (67%). MVA resulted in a single variable model - OC 
V62.5Gy - for mucositis (OR=1.04, p=0.004); a 3-variable 
model for dysphagia including OC V62.5Gy (OR=1.03, p=0.05), 
minimum dose to PCM (OR=1.06, p=0.05) and SL V30Gy 
(OR=1.05, p=0.37); a 2-variable model for xerostomia 
including parotid glands V72.5Gy (OR=1.09, p=0.21) and OC 
V65Gy (OR=1.06, p=0.01). Calibration was good in all cases. 
Calculation of residuals allowed the identification of high-
residual pts, 15 (12%) for mucositis and 9 (7%) for dysphagia, 
who exhibited toxicity despite their low MVA prediction 
suggesting a potential radiosensitivity. Conversely, 9 (7%) 
low-residual pts for xerostomia who did not exhibit toxicity 
despite their high MVA prediction might imply a potential 
radioresistance. 
Conclusions: Preliminary analysis suggests a dose-response 
relationship for acute mucositis, dysphagia and xerostomia. 
Residual pts with respect to dosimetric models were 
identified and could be good candidates for analysis of 
genetic determinants of radioinduced toxicity.  
   
 
EP-1477   
Commissioning radiobiological metrics for 3D patient-
specific quality assurance 
F. Clemente Gutierrez1, C. Perez Vara1, M. Clavo Herranz2, C. 
Lopez Carrizosa2, C. Ibanez Villoslada2, J. Saez Garrido2, M.L. 
Couselo Paniagua2, J. Zapatero Ortuno2, M. Martin de Miguel2, 
M. Dominguez Morcillo2, A. Calapaqui Teran2, M. Guijarro 
Verdu2, V. Jerviz Guia2 
1Hospital Central de la Defensa Gómez Ulla, Medical Physics, 
Madrid, Spain  
2Hospital Central de la Defensa Gómez Ulla, Radiation 
Oncology, Madrid, Spain  
 
Purpose/Objective: The patient-specific QA programs have 
evolved substantially during the last years. The transition 
from point and 2D verifications to 3D verifications on patient 
anatomy is being carried out. This information allows to 
introduce DVH-based metrics in QA process. In addition, the 
quality of a RT plan can be judged by radiobiological 
parameters. This work shows the clinical introduction of 
radiobiological metrics (gEUD, TCP and NTCP) in patient-
specific QA by means of a benchmark test described in the 
AAPM report of the Task Group 166. 
Materials and Methods: The Compass system is capable to 
calculate and reconstruct dose on patient anatomy. In order 
to evaluate the introduction of radiobiological metrics in 
patient-specific QA process, a simple plan test was 
performed using a benchmark case taken from AAPM TG-166 
report. This case consisted on a single 6 MV, 20 x 20 cm2 
photon beam incident on a cubic and homogeneous phantom 
at 100 cm SSD, with four simple structures (three 
rectangular, one triangular) defined in the report. A dose of 
72 Gy in 40 fractions was prescribed to a point at 6 cm depth 
along the central axis. This plan was generated by the TPS 
(Monaco 3.1, Elekta) and delivered in the treatment unit 
(Synergy, Elekta). During this delivery, beam was measured 
by the Compass system. It provided the redundant calculation 
and the dose reconstruction from measurements over the TG-
166 structures contoured on benchmark phantom. gEUD, TCP 
(Poisson, Sigmoidal and Niermierko models) and NTCP (LKB 
and Niermierko models) were determined for the previous 
structures, from the TPS, Compass calculated and Compass 
reconstructed data. 
Results: The relative mean differences for all structures 
between Compass and TPS for gEUD parameter were 
(0.25±0.78)% and (0.24±0.77)% for Compass dose calculation 
and reconstruction results, respectively. The mean 
differences for the TCP models (Poisson, Sigmoidal and 
Niemierko, respectively) were (-0.24±0.33)%, (-0.18±0.33)% 
and (-0.19±0.26)% for the Compass dose calculation results, 
and (0.34±0.53)%, (0.18±0.34)% and (0.16±0.24)% for the 
Compass dose reconstruction results. For the NTCP models 
(LKB and Niemierko, respectively), the mean discrepancies 
were (-0.13±0.72)% and (0.37±0.60)% for the Compass dose 
calculation results and (0.30±0.85)% and (-0.19±0.77)% for 
the Compass dose reconstruction results. 
Conclusions: Mean discrepancies were below 1% for all the 
radiobiological parameters analyzed in this benchmark case. 
Radiobiological parameters are powerful evaluation tools for 
radiation therapy treatment plans. 3D dose verification 
systems allow to introduce radiobiological data in the 
patient-specific QA process, as an additional metric in a 
pretreatment verification program.  
